All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sargramostim
Therapeutic Area: Infections and Infectious Diseases Product Name: Leukine
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2021
Details:
SARPAC Clinical Trial of Leukine® met the primary endpoint of improved oxygenation after five days of treatment with inhaled sargramostim in combination with standard of care (SOC) compared with SOC alone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
Details:
The indication for extended use of remdesivir, if approved, would allow the antiviral treatment to be given to more patients as coronavirus infections surge and healthcare systems are pressured by emerging, highly transmissible variants of the virus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Veklury
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
Details:
Veklury is currently authorised for use in adults and adolescents (from 12 years of age and weighing at least 40 kilograms) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at the start of treatment).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2021
Details:
Gilead has issued a statement responding to the new COVID-19 strains discovered in the UK and South Africa, maintaining that its antiviral drug remdesivir should continue to be effective against the variants.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Heparin Sodium
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
Three clinical trial platforms spanning five continents in more than 300 hospitals have been working together to test whether there is a greater benefit of full doses of heparin to treat moderately ill hospitalized adults with COVID-19 compared to the lower heparin dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tocilizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent. The findings come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Apremilast,Eritoran,Hydrocortisone
Therapeutic Area: Infections and Infectious Diseases Product Name: Otezla
Highest Development Status: Phase IV Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Amgen & Eisai to participate in the immune modulation domain of REMAP-COVID, an adaptive clinical trial to test interventions for patients hospitalized with COVID-19. Amgen’s Apremilast & Eisai’s Eritoran to be evaluated across multiple international trial sites.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BCG vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IV Product Type: Vaccine
Partner/Sponsor/Collaborator: Hellenic Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2020
Details:
BCG-vaccinated participants had their first infection on average 16 weeks after vaccination, compared to 11 weeks for the placebo group. There was no difference in side effects.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
